Phase I trial of an anti-cd19 deglycosylated ricin a chain immunotoxin in non-hodgkin's lymphoma: Effect of an intensive schedule of administration

Journal of Immunotherapy

Volumn 18, Issue 4, 1995, Pages 231-241

  Conry, Robert M ^a   Khazaeli, M B ^a   Saleh, Mansoor N ^a   Ghetie, Victor ^b   Vitetta, Ellen S ^b   Liu, Tiepu ^a   LoBuglio, Albert F ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Immunotherapy; Immunotoxin; Monoclonal antibody; Non Hodgkin's lymphoma; Ricin A chain

Indexed keywords

CD19 ANTIGEN; IMMUNOTOXIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HD37; RICIN A; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BLOOD LEVEL; BRONCHOPNEUMONIA; CANCER IMMUNOTHERAPY; CAPILLARY PERMEABILITY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG HALF LIFE; FEMALE; HUMAN; HYPOALBUMINEMIA; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHODGKIN LYMPHOMA; ORTHOSTATIC HYPOTENSION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RHABDOMYOLYSIS; WEIGHT GAIN;

ADULT; AGED; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIGENS, CD19; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLYCOSYLATION; HUMANS; IMMUNOTOXINS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; RICIN;

EID: 0029552255     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199511000-00004     Document Type: Article

References (30)

1. Endo Y, Mitsui K, Motizuki M, et al. The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. J Biol Chem 1987;262:5908-12.
2. Olsnes S, Sandvig K, Petersen OW, et al. Immunotoxins - entry into cells and mechanisms of action. Immunol Today 1989;10:291-5.
3. Youle RJ, Neville DM. Kinetics of protein synthesis inactivation by ricin-anti-Thy 1.1 monoclonal antibody hybrids. J Biol Chem 1982;257:1598-601.
4. Lambert JM, McIntyre G, Gauthier MN, et al. The galactose-binding sites of the cytotoxic lectin ricin can be chemically blocked in high yield with reactive ligands prepared by chemical modification of glycopeptides containing triantennary N-linked oligosaccharides. Biochemistry 1991;30:3234-47.
5. Oratz R, Speyer JL, Wernz JC, et al. Anti-melanoma monoclonal antibody ricin A chain immunoconjugate (XMMME-001-RTA) plus cyclophosphamide in the treatment of metastatic malignant melanoma: results of a phase II trial. J Biol Response Mod 1990;9:345-54.
6. Spitler LE, del Rio M, Khentigan A, et al. Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin. Cancer Res 1987;47:1717-23.
7. Weiner LM, O’Dwyer J, Kitson J, et al. Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9- recombinant ricin A chain immunoconjugate. Cancer Res 1989;49:4062-7.
8. Byers VS, Rodvien R, Grant K, et al. Phase I study of monoclonal antibody ricin A chain immunotoxin XOMAZYME- 791 in patients with metastatic colon cancer. Cancer Res 1989;49:6153-60.
9. Hertler AA, Schlossman DM, Borowitz MJ. A phase I study of T101-ricin A chain immunotoxin in refractory chronic lymphocytic leukemia. J Biol Response Mod 1988;7:97-113.
10. Blakey DC, Skilleter DN, Price RJ, Thorpe PE. Uptake of native and deglycosylated ricin A-chain immunotoxins by mouse liver parenchymal and non-parenchymal cells in vitro and in vivo. Biochim Biophys Acta 1988;968:172-8.
11. Blakey DC, Watson GJ, Knowles PP, Thorpe PE. Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti-Thy 1.1 antibody. Cancer Res 1987;47:947-52.
12. Bourrie BJ, Casellas P, Glythman HE, Jansen FK. Study of the plasma clearance of antibody-ricin-A-chain immunotoxins. Evidence for specific recognition sites on the A chain that mediate rapid clearance of the immunotoxin. Eur J Biochem 1986;155:1-10.
13. Hertler AA, Frankel AE. Immunotoxins: a clinical review of their use in the treatment of malignancies. J Clin Oncol 1989;7:1932-42.
14. Thorpe PE, Detre SI, Foxwell BMJ, et al. Modification of the carbohydrate in ricin with metaperiodate-cyano-borohydride mixtures: effects of toxicity and in vivo distribution. Eur J Biochem 1985;147:197-206.
15. Thorpe PE, Wallace PM, Knowles PP, et al. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A chain and hindered disulfide linkages. Cancer Res 1988;48:6396-403.
16. Amlot PL, Stone MJ, Cunningham D, et al. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood 1993;82:2624-33.
17. Vitetta E, Stone M, Amlot P, et al. Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res 1991;51:4052-8.
18. Grossbard ML, Lambert JM, Goldmacher VS, et al. Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. J Clin Oncol 1993;11:726-37.
19. Sausville EA, Headlee D, Stetler-Stevenson M, et al. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B cell lymphoma: a phase I study. Blood 1995;85:3457-65.
20. Khazaeli MB, Saleh MN, Wheeler RH, et al. Phase I trial of multiple large doses of murine monoclonal antibody C017-1A. II. Pharmacokinetics and immune response. J Natl Cancer Inst 1988;80:937-42.
21. 131I-chimeric mouse/human B72.3 (human γ4) monoclonal antibody in humans. Cancer Res 1991;51:5461-6.
22. Meredith RF, Khazaeli MB, Plott WE, et al. Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancer. J Nucl Med 1992;33:23-9.
23. LoBuglio AF, Wheeler RH, Trang J, et al. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci USA 1989;86:4220-4.
24. The Non-Hodgkin’s Lymphoma Pathologic Classification Project: NCI sponsored study of classifications of non-Hodgkin’s lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982;49:2112-35.
25. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993;329:1219-24.
26. Grossbard ML, Gribben JG, Freedman AS, et al. Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin’s lymphoma. Blood 1993;81:2263-71.
27. Byers VS, Baldwin RW. Therapeutic strategies with monoclonal antibodies and immunoconjugates. Immunology 1988;65:329.
28. Soler-Rodriguez A-M, Ghetie M-A, Oppenheimer-Marks N, Uhr JW, Vitetta ES. Ricin A-chain and ricin A-chain immunotoxins rapidly damage human endothelial cells: implications for vascular leak syndrome. Exp Cell Res 1993;206:227.
29. Rosenberg SA, Lotze MT. Cancer immunotherapy using interleukin-2 and interleukin-2 activated lymphocytes. Ann Rev Immunol 1986;4:681.
30. Edwards MJ, Heniford BT, Slar EA, Doak KW, Miller FN. Pentoxifylline inhibits interleukin-2-induced toxicity in C57BL/6 mice but preserves antitumor efficacy. J Clin Invest 1992;90:637.